Glucose-dependent Insulinotropic Polypeptide Research

Qiao Y, Zhou F, Mao T, Gao L

Glucose-dependent insulinotropic polypeptide (GIP), once the overlooked sibling of the incretin family, is now experiencing a research renaissance. Historically, its therapeutic development was hindered by a seemingly diminished insulinotropic effect in type 2 diabetes (T2DM), its paradoxical sti...

Warden BA, Duell PB, Bucheit JD, Purnell JQ

Obesity is a chronic disease, rooted in genetic predisposition and homoeostatic counter-regulatory adaptive and hormonal responses, with escalating prevalence rates and numerous associated health consequences.Historically, interventions beyond lifestyle for the treatment of obesity have been unde...

Amrein K, Kim SH, Brath H, Fasching P, Pittas AG

Prediabetes is common worldwide and offers a critical opportunity for interventions to prevent type 2 diabetes. Vitamin D has biologically plausible effects on beta cell function, insulin sensitivity, and the immune system, and observational studies consistently associate higher 25-hydroxyvitamin...

Narla S, Narla RR, Corbett JA

The prevalence of obesity and type 2 diabetes mellitus (T2DM) continues to rise in the United States (U.S.) and worldwide, contributing to substantial morbidity and mortality through metabolic dysfunction and systemic inflammation. Glucagon-like peptide-1(GLP-1)-based therapies, originally develo...

Corrêa LMA, Mazur GR, Santiago CBG, Dante LE, de Marco PS, Ferrés PBS et al.

Post-transplant metabolic management remains challenging, as immunosuppression exacerbates diabetes and obesity, threatening graft outcomes. While incretin-based therapies have transformed metabolic care, data on tirzepatide-a dual GIP/GLP-1 receptor agonist-in solid organ transplantation (SOT) a...

Rose BD, Kreuch D, Wu T, Horowitz M, Rayner CK, Page AJ et al.

Foods and beverages sweetened with non-nutritive sweeteners (NNSs) are increasingly common in modern diets and widely promoted as healthy alternatives to their sugar-sweetened counterparts, with attendant benefits for individuals with preclinical or clinical metabolic disease. Despite this positi...

Leong D, Gong S, Sattar N, Narayan V, Reizine NM, Gerstein H et al.

Incretin mimetics (glucagon-like peptide-1 receptor agonists and dual glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor agonists) are paradigm changing for managing obesity, diabetes, and cardiovascular risk. These phenotypes are also associated with elevated risk for ...

Schmidt PHS, de Souza VSN, Machado LG, Rodrigues JVA, da Cruz JVR, de Souza LSN et al.

To evaluate the effects of tirzepatide on physical function in adults with overweight or obesity.We searched PubMed, Embase, and the Cochrane Library up to July 20, 2025 for randomized controlled trials (RCTs) comparing once-weekly tirzepatide 10 or 15 mg with placebo and reporting validat...

Kawahara NT, Abujamra S, Bremm LC, Kruel N, Kawahara L, Nocca D et al.

Laparoscopic sleeve gastrectomy (LSG) and Roux-en-Y gastric bypass (RYGB) remain the most commonly performed bariatric operations worldwide; however, LSG is increasingly associated with weight regain, and the optimal revisional strategy remains debated. Bypass procedures offer potent metabolic ef...

Lee D, Kahlon R, Deng J, Kluttig K, Morrow NM, Mulvihill EE et al.

β-cell adaptation to maternal insulin resistance of pregnancy involves up-regulation of β-cell mass and function, a process we previously showed depends on prolactin receptor (PRLR) signaling. Emering evidence in humans suggests that prolactin signaling may also influence β-cell...

Makkena HB

Background The rapid adoption of incretin-based therapies for obesity has raised questions regarding their comparative safety profiles. While the gynecological safety of glucagon-like peptide-1 (GLP-1) receptor agonists is documented, the potential risks associated with dual glucose-dependent ins...

Kamath S, Chan NSL, Joyce P

Glucagon-like peptide-1 (GLP-1) receptor agonists have transformed the management of type 2 diabetes mellitus (T2DM) and obesity, yet their interactions with the gut microbiome remain an emerging frontier in pharmacological and metabolic research. Mounting evidence suggests that the gut microbiot...

Patel NP, Hussain K

Talamini F, Grassi M, Altoè G, Brattico E, Caclin A, Carretti B et al.

The Music Ensemble dataset is a large-scale, cross-national database that provides detailed information about the musical, cognitive, personality, and demographic profiles of young adult musicians and nonmusicians. Data were collected from 1438 participants (aged 18-30) across thirty-five researc...

Guo B, Yue Y, Luo X, Zhou Y, Yu J, Yang X et al.

Our understanding of the intrinsic mechanisms that drive the regeneration of damaged axons after a spinal cord injury is still limited. Microtubules are core components of the eukaryotic cytoskeleton and are essential for axonal growth, in part because their stability is governed by post-translat...

Kahles F, Birkenfeld AL, Marx N

The incretin hormone glucagon-like peptide-1 (GLP-1) exerts potent effects on glucose metabolism, prompting the development of therapeutic strategies that enhance activity of the GLP-1 receptor (GLP-1R) pathway. Inhibitors of dipeptidyl peptidase 4 (DPP-4) prolong the half-life of endogenous GLP-...

Valente V, Beer BN, Savarese G

Heart failure with preserved ejection fraction (HFpEF) represents approximately half of all heart failure cases and poses a growing global health challenge driven by an ageing population and an increasing comorbidity burden. Once regarded as a condition without effective, evidence-based therapy, ...

Singh P, Tripathy DB, Kumar G

Type 2 Diabetes Mellitus (T2DM) is a global health challenge characterised by pathophysiological diversity, resulting in significant inter-individual variability in drug response. Pharmacogenomics (PGx) offers a powerful approach to personalise T2DM management by linking genetic makeup to therape...

Sekhon S, Kahlon I, Latson W

Tirzepatide has been approved for the management of obesity, obstructive sleep apnea, and type 2 diabetes mellitus; while gastrointestinal side effects are commonly seen, ischemic colitis has been only rarely described. We present the case of a 32-year-old woman with no prior medical history...

Kalamaras H, White RT, Coon SA, Perkel M, Elmaoued AA

Incretin therapies have shown promise in managing antipsychotic-associated weight gain and psychological benefits in individuals with mental health disorders. In populations at high risk for suicidal behaviors, it is crucial to understand how these therapies affect risk of suicidality or self-har...